Ampersand Biomedicines

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,

The number of venture capital mega-rounds of $100m or more plummeted from 11 in January to just three in February, but appear to be on the rise again with five as of mid-March. Flagship Pioneering’s l

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office